Omitting bolus 5-fluorouracil (5-FU) from combination chemotherapy for gastrointestinal (GI) cancers did not adversely affect survival and was associated with less toxicity, a review of a large ...
The FDA added a boxed warning to capecitabine and 5-FU labels, noting the risk of serious adverse reactions or death in patients with complete DPD deficiency. Capecitabine and 5-FU are both nucleoside ...
A new case report was published in Volume 12 of Oncoscience on December 23, 2025, titled "Silent toxicity: A rare case of 5-fluorouracil-induced hyperammonemic encephalopathy." In this report, Areti ...
June 17, 2009 (Orlando, Florida) — There is now an antidote for clinicians to use in the event of an overdose of the commonly used chemotherapy 5-fluorouracil (5-FU), according to a poster ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Administration of 5-FU bolus did not affect survival for ...
However, omission does result in reductions in neutropenia, thrombocytopenia, and use of granulocyte colony-stimulating factor. HealthDay News — Omission of 5-fluorouracil (5-FU) from the first-line ...
Reducing regorafenib toxicity by combining with dual JAK-HDAC inhibitor in colorectal cancer. Safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by ...
Purple Biotech Ltd. announced a significant study revealing that their drug NT219, combined with 5-fluorouracil (5-FU), effectively inhibits colorectal cancer brain metastasis by targeting the IRS2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results